title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Study population and recruitment | SECONDARY | Schools, pupils and staff were recruited using a two-stage randomized cluster design with proportional allocation by province and sociodemographic background. In the first stage, 41 clusters were identified in which one primary school and one secondary school were selected at random from a list of all Belgian schools p... | PMC10185463 | |
Sample size | SECONDARY | A sample size of 800 pupils and 400 staff at each school level (primary and secondary schools) was calculated to estimate the seroprevalence with a margin of error of 2.3% for pupils and 3.0% for staff, assuming a seroprevalence of 6% among pupils and 10% among staff and a cluster design effect of two. All participants... | PMC10185463 | |
Data collection | The local study coordinator – a staff member of the participating school – collected the data on the implementation of IPC measures via a secured online questionnaire using the ‘LimeSurvey’ platform (LimeSurvey version 3.22.24 + 2,000,630; see Supplement During each data collection period, the prevalence of anti-SARS-C... | PMC10185463 | ||
Implementation of IPC measures | The implementation of IPC measures in Belgian schools is presented using data from three data collection periods (December 2020/January 2021, March 2021 and May/June 2021).IPC measures were grouped according to the target age as: [For each data collection period, we reported the number and proportion of schools that im... | PMC10185463 | ||
Relation between the implementation of IPC measures and prevalence of anti-SARS-CoV-2 antibodies | SECONDARY | Based on the data collected during the first data collection period (December 2020/January 2021), we assessed whether the implementation of IPC measures was associated with the prevalence of anti-SARS-CoV-2 antibodies among pupils and staff in primary and secondary schools. Only schools that provided an answer for at l... | PMC10185463 | |
Ethics approval | The study was approved by the Medical Ethics Committee of the University Hospital Ghent (reference: B6702020000744—BC-08564). Before enrolment, written informed consent was obtained from staff and parents of participating pupils, and informed assent was obtained from pupils. | PMC10185463 | ||
Results | PMC10185463 | |||
Participating schools | SECONDARY, RECRUITMENT | We contacted 98 primary and 108 secondary schools of which 44 primary and 40 secondary schools agreed to participate. Of these 84 schools, 45 belonged to the Dutch and 39 to the French language network. All but one school (Eighty-one schools (43 primary and 38 secondary) fulfilled the requisite 10 (out of a total of 14... | PMC10185463 | |
Relation between IPC measures implementation and prevalence of anti-SARS-CoV-2 antibodies among pupils and staff | Figure Prevalence of anti-SARS-CoV-2 antibodies according to the degree of IPC measure implementationData collected at December 2020/January 2021 in Belgian schools among pupils and staff. The black lines indicate the upper and lower 95% confidence intervals. When this analysis was repeated for each subcategory of meas... | PMC10185463 | ||
Discussion | MAY, SECONDARY, HOLIDAY | Apart from some ventilation and physical distancing measures, most IPC measures were implemented by more than 60% of primary and secondary schools. Overall, the implementation of IPC measures was similar in primary and secondary schools. However, since reopening in May 2020, more primary than secondary schools reported... | PMC10185463 | |
Conclusion | SECONDARY | Most Belgian primary and secondary schools of both language networks complied relatively well with recommended IPC measures. Poor implementation of all such IPC measures together and separately, by ventilation, hygiene and physical distancing subcategory, showed an increase in the prevalence of anti-SARS-CoV-2 antibodi... | PMC10185463 | |
Acknowledgements | INFECTIOUS DISEASES, SECONDARY | All participants: Primary and secondary schools, school staff, pupils and their parentsBiological sample collection: All participating nursesBiological sample transportation: Sciensano’s Sample Management (BBC transport services)Biological sample analysis: Caroline Rodeghiero and Fabienne Jurion, expert technicians at ... | PMC10185463 | |
Authors’ contributions | MR | RECRUITMENT | Concept, design, protocol writing: JM, MR and ED; Recruitment of participants and logistical coordination: MC, IK and MV; Administrative, technical, or material support: all authors; Biological sample collection and transport: MC and IK; Biological sample analysis: ID; Epidemiological data collection: IK, ED; Epidemiol... | PMC10185463 |
Funding | This study was funded by the Belgian government (COVID-19 SC_044A) through Sciensano, the Belgian institute of Public Health, Brussels, Belgium. | PMC10185463 | ||
Availability of data and materials | The data used in the current study are not publicly available due to privacy concerns, but data that support the current findings are available from the corresponding author on reasonable request. | PMC10185463 | ||
Declarations | PMC10185463 | |||
Ethics approval and consent to participate | The study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of the University Hospital Ghent (reference: B6702020000744—BC-08564). Written informed consent was obtained from all staff and parents of participating pupils before enrolment. Additionally, written info... | PMC10185463 | ||
Consent for publication | Not applicable. | PMC10185463 | ||
Competing interests | The authors declare no competing interests. | PMC10185463 | ||
References | PMC10185463 | |||
Background | cancer | CANCER, METASTATIC BLADDER CANCER | Patient-reported outcomes (PROs) are getting widely implemented, but little is known of the impact of applying PROs in specific cancer diagnoses. We report the results of a randomized controlled trial (RCT) of the active use of PROs in patients with locally advanced or metastatic bladder cancer (BC) undergoing medical ... | PMC10562329 |
Methods | We recruited patients from four departments of oncology from 2019 to 2021. Inclusion criteria were locally advanced or metastatic BC, initiating chemo- or immunotherapy. Patients were randomized 1:1 between answering selected PRO-CTCAE questions electronically once weekly with a built-in alert-algorithm instructing pat... | PMC10562329 | ||
Results | METASTATIC DISEASE | 228 patients with BC were included, 76% were male. 141 (62%) of the patients had metastatic disease. 51% of patients in the IA completed treatment vs. 56% of patients in the CA, OR 0.83 (95% CI 0.47–1.44, | PMC10562329 | |
Conclusions | This RCT did not show an effect of PRO on completion of treatment, hospitalizations or OS for BC patients during MOT despite a high level of patient and clinician compliance. The lack of real-time response to alerts remains the greatest limitation to this study. | PMC10562329 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s41687-023-00640-5. | PMC10562329 | ||
Keywords | Open access funding provided by Royal Library, Copenhagen University Library | PMC10562329 | ||
Introduction | Bladder cancer | BLADDER CANCER, DISEASE | Bladder cancer (BC) patients with advanced stages of disease have a poor prognosis [In this study we report the effect of weekly ePROs as an intervention compared to standard of care for BC patients receiving chemo- or immunotherapy with the aim of reducing rate of hospital admissions during treatment and prevent early... | PMC10562329 |
Methods | PMC10562329 | |||
Patients | urothelial carcinoma of the bladder, Cancers, muscle-invasive bladder cancer | ADVERSE EVENT, CANCERS | From 15th of January 2019 all patients with urothelial carcinoma of the bladder initiating chemo- or immunotherapy (cisplatin/gemcitabine, carboplatin/gemcitabine, pembrolizumab or vinflunin) as neoadjuvant treatment for muscle-invasive or locally advanced BC (from here on referred to as locally advanced BC) or palliat... | PMC10562329 |
The control arm | Patients assigned to the control arm (CA) followed standard procedure for handling of side effects and symptoms as informed by the treating department. The patients completed QoL questionnaires once every three weeks, as shown in Table Frequency of questionnaires and clinical visits for control arm | PMC10562329 | ||
Statistical analysis | Musoro, death | On the basis of rates of treatment completion from a previous study and literature review, the current study was planned to include 230 patients. Prior data indicated that the rate of treatment cessation among controls was 50% [The proportion of patients experiencing early treatment cessation, hospitalization or dose r... | PMC10562329 | |
Ethical considerations | The study was approved by the Danish Data Protection Agency (suite nb: RH-2017–348), registered at | PMC10562329 | ||
Results | deaths | PATHOLOGY | From 22nd January 2019 to 19th March 2021, we enrolled a total of 230 patients. Two patients were later excluded due to final pathology report requiring a different treatment than that of our inclusion criteria and another did not initiate treatment. The analysis therefore included 228 patients, Fig. CONSORT diagram of... | PMC10562329 |
Discussion | toxicity, cancer, anxiety, breast cancer | CANCER, METASTATIC MELANOMA, SIDE EFFECT, BREAST CANCER | In this multicenter randomized trial testing the active use of PROs during systemic oncological treatment for BC patients, we found a high rate of completed questionnaires and a high rate of clinician viewing of the patient-reported symptoms. For the primary endpoints, no statistically significant differences were foun... | PMC10562329 |
Conclusions | bladder cancer | BLADDER CANCER | Conclusively, we did not find ePROs effective for the bladder cancer patients in relation to the chosen endpoints. We observed a high level of clinician engagement in using the ePROs and a positive impact on patients’ emotional functioning. Our study demonstrates the caveats in applying PROs across patient groups as a ... | PMC10562329 |
Acknowledgements | A special thanks to all the patients participating in this randomized study and all prior studies leading up to the current. Also, endless appreciation to the clinical and study staff at all four hospital sites throughout the study period. | PMC10562329 | ||
Author contributions | HL | RHD | GAT: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Validation; Visualization; Roles/Writing – original draft; Writing – review & editing. CJ: Conceptualization; Funding acquisition; Methodology; Resources; Supervision; Wr... | PMC10562329 |
Funding | Cancer | LARSEN, CANCER | Open access funding provided by Royal Library, Copenhagen University Library Danish Cancer Society, Dagmar Marshalls Fond, Einar Willumsens Mindelegat, A.P. Møller Lægefonden, Christian Larsen og Dommer Ellen Larsens Legat, Rigshospitalets Fond til støtte for onkologiske formal, Onkologisk Forskningsfond and Rigshospit... | PMC10562329 |
Availability of data and materials | The data that support the findings of this study are available from Gry Assam Taarnhøj but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission... | PMC10562329 | ||
Declarations | PMC10562329 | |||
Ethics approval and consent to participate | The study was approved by the Danish Data Protection Agency (suite nb: RH-2017–348), registered at | PMC10562329 | ||
Consent for publication | Not applicable. | PMC10562329 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10562329 | ||
References | PMC10562329 | |||
Background | cancer, anemia | CANCER, ANEMIA, BLOOD | Gynecologic cancer has a high frequency of anemia, which is associated with increased morbidity and mortality. Blood transfusion is used to correct anemia, but carries its own side effects and problems in the blood supply have been emerging. As such, methods other than transfusion are needed to correct anemia in patien... | PMC10359505 |
Primary Objective | anemia | GYNECOLOGIC CANCER, ANEMIA | To determine whether intravenous administration of high-dose iron supplements before and after surgery as a patient blood management program is helpful in correcting anemia and reducing the frequency of transfusion in patients with gynecologic cancer. | PMC10359505 |
Study Hypothesis | Patient blood management will reduce the transfusion rate by up to 25%. | PMC10359505 | ||
Trial Design | This prospective, multicenter, interventional, randomized controlled study will consist of three steps. In step 1, the safety and effectiveness of patient blood management for surgical patients before, during, and after surgery will be evaluated. In steps 2 and 3, the safety and effectiveness of patient blood managemen... | PMC10359505 | ||
Major Inclusion/Exclusion Criteria | gynecologic cancer | OVARIAN CANCER, ENDOMETRIAL CANCER, GYNECOLOGIC CANCER, IRON DEFICIENCY, CERVICAL CANCER | Patients who are diagnosed with gynecologic cancer (ie, endometrial cancer, cervical cancer, ovarian cancer) and scheduled for surgery will be included and their iron deficiency status will be assessed. Only those with a pre-operative hemoglobin level of 7 g/dL or higher will be included. Patients who underwent neoadju... | PMC10359505 |
Primary Endpoint | Rate of transfusion within 3 weeks after surgery. | PMC10359505 | ||
Sample Size | Eligible participants will be randomly assigned in a 1:1 ratio (167 patients each) into the patient blood management group and the conventional management group. | PMC10359505 | ||
Estimated Dates for Completing Accrual and Presenting Results | RECRUITMENT | Patient recruitment will be completed by mid-2025, and management and follow-up will be completed by the end of 2025. | PMC10359505 | |
Trial Registration Number | PMC10359505 | |||
Introduction | cancer, Anemia, anemia | GYNECOLOGIC CANCER, CANCER, ACUTE BLOOD LOSS, SOLID TUMORS, ANEMIA, ANEMIA, BLOOD | Anemia is prevalent in cancer patients and affects 20–80% of patients with solid tumors.Gynecologic cancer is associated with a high frequency of anemia (~85%). The frequency of anemia and blood transfusion is also reported to be very high during surgery, chemotherapy, and radiation therapy, which are the mainstay of t... | PMC10359505 |
Methods and Analysis | PMC10359505 | |||
Trial Design | ONCOLOGY | This is a prospective, multicenter, interventional, comparative, randomized controlled trial involving a total of 15 institutions in South Korea, of which the Asan Medical Center (Seoul, South Korea) will serve as the leading institution. This study was approved by the institutional review board of Asan Medical Center ... | PMC10359505 | |
Step 1: Anemia Correction in Surgery | anemia | BLOOD, ANEMIA | Blood tests will be performed between 2 and 6 weeks before surgery and anemia will be corrected according to the test results for each group as follows. The treatment and examination schedule for step 1 is shown in Examination and treatment of anemia in step 1 (surgery). Hb, hemoglobin; PBM, patient blood management; p... | PMC10359505 |
Patient Blood Management Group | HEMODYNAMIC INSTABILITY | If the hemoglobin level is between 7 g/dL and 12 g/dL in the preoperative blood test, 1000 mg of ferric carboxy-maltose will be administered between 2 and 6 weeks before surgery. During surgery, the need for transfusion will be decided according to the judgment of the attending surgeon and anesthesiologist in case of h... | PMC10359505 | |
Conventional Management Group | Cancer | ONCOLOGY, HEMODYNAMIC INSTABILITY, COMPLICATIONS, CANCER | If the hemoglobin level is between 8 g/dL and 10 g/dL, one pack of RBC will be transfused and, if the hemoglobin level is 8 g/dL or less, two packs of RBC will be transfused. Erythropoietin and oral iron supplements will be allowed, but not intravenous iron supplements. During surgery, the need for transfusion will be ... | PMC10359505 |
Step 2: Anemia Correction in Adjuvant (Chemo)radiation Therapy | Anemia, anemia | ANEMIA, ANEMIA | Anemia will be corrected after performing blood tests on the day of computed tomography (CT) simulation, during (concurrent chemo-) radiation therapy ((CC)RT), and every 3 weeks (visit window±1 week) after the end of treatment. The hemoglobin level will be re-evaluated at 3 weeks after the end of treatment. The treatme... | PMC10359505 |
Patient Blood Management Group | If the hemoglobin level is between 7 g/dL and 12 g/dL in the pre-treatment blood test, 1000 mg of ferric carboxy-maltose will be administered; if the hemoglobin level is 7 g/dL or less, two packs of RBC will be transfused. | PMC10359505 | ||
Conventional Management Group | If the hemoglobin level is between 8 g/dL and 10 g/dL, one pack of RBC will be transfused; if the hemoglobin level is 8 g/dL or less, two packs of RBC will be transfused. Erythropoietin and oral iron supplements will be allowed but not intravenous iron supplements. | PMC10359505 | ||
Step 3: Anemia Correction in Adjuvant Chemotherapy | Anemia, anemia | ANEMIA, ANEMIA | Anemia will be assessed by performing blood tests the day before the start of chemotherapy and every two cycles during chemotherapy. The hemoglobin level will be re-evaluated at 3 weeks after the end of treatment. The treatment and examination schedule for step 3 is shown in Examination and treatment of anemia in step ... | PMC10359505 |
Patient Blood Management Group | If the hemoglobin level is between 8 g/dL and 12 g/dL in the pre-treatment blood test, 1000 mg of ferric carboxy-maltose will be administered; if the hemoglobin level is 8 g/dL or less, two packs of RBC will be transfused. Erythropoietin may be used in patients with a symptomatic hemoglobin level of 12 g/dL or less or ... | PMC10359505 | ||
Conventional Management Group | If the hemoglobin level is between 8 g/dL and 10 g/dL, one pack of RBC will be transfused; if the hemoglobin level is 8 g/dL or less, two packs of RBC will be transfused. Erythropoietin and oral iron supplements will be allowed but not intravenous iron supplements. | PMC10359505 | ||
Participants | PMC10359505 | |||
Inclusion Criteria | ovarian cancer | ONCOLOGY, OVARIAN CANCER | Study patients must satisfy all of the following selection criteria: (1) women aged 20–80 years; (2) untreated histologically diagnosed cervical cancer, endometrial cancer, or ovarian cancer (including cases diagnosed by imaging without biopsy in the case of ovarian cancer); (3) Eastern Cooperative Oncology Group perfo... | PMC10359505 |
Exclusion Criteria | allergic, tumor, cancer, non-melanoma skin cancer, cancer of the stomach and bladder | CANCER, TUMOR, IRON OVERLOAD, DISORDERS | The exclusion criteria are as follows: (1) unable to provide informed consent on their own; (2) allergic to existing iron preparations; (3) underwent neoadjuvant chemotherapy or pre-operative radiation therapy; (4) have had or received cancer treatment within 5 years, except for non-melanoma skin cancer, cervical intra... | PMC10359505 |
Endpoints | anemia | ADVERSE EVENTS, SECONDARY, ANEMIA | The primary endpoint is the rate of transfusion within 3 weeks after surgery. The secondary endpoints include transfusion rate within 3 weeks after radiation and chemotherapy, and the comparison of hemoglobin levels, frequency of anemia and blood transfusion before adjuvant therapy, frequency of delayed adjuvant therap... | PMC10359505 |
Sample Size | We performed sample size calculation through the Z-test with unpooled variance. Previous studies showed that the expected transfusion rate without patient blood management is 40%, | PMC10359505 | ||
Randomization and Blinding | cancer | CANCER | Patients will be randomly assigned in a 1:1 ratio to the patient blood management group and the conventional management group. A randomization table will be prepared using SAS software (SAS Institute, Cary, North Carolina, USA) by an independent statistician and study patients will be assigned using the stratified bloc... | PMC10359505 |
Statistical Methods | gynecologic cancer | GYNECOLOGIC CANCER | The main purpose of this study is to compare the transfusion rate according to the implementation of patient blood management in patients with gynecologic cancer undergoing surgery. For other safety endpoints such as laboratory tests and vital signs, continuous data will be presented using descriptive statistics (ie, m... | PMC10359505 |
Ethics statements | PMC10359505 | |||
Patient consent for publication | Consent obtained directly from patient(s) | PMC10359505 | ||
Ethics approval | This study involves human participants and was approved by the institutional review board of Asan Medical Center Approval ID: 2022-1674. Approval date December 6, 2022. Participants gave informed consent to participate in the study before taking part. | PMC10359505 | ||
References | PMC10359505 | |||
Background | type 2 diabetes | TYPE 2 DIABETES | The prevalence of type 2 diabetes is increasing among adolescents and clear strategies are needed to prevent it. The aim of this study was to determine the effect of peer education on knowledge, health beliefs and preventive behaviors of type 2 diabetes in female adolescents. | PMC10276363 |
Methods | AIDS | In this cluster randomized trial study, 168 students (84 people in each group) were enrolled. The data collection instrument was a questionnaire of knowledge (30 questions), health beliefs (16 questions) and behavior (20 questions) whose validity and reliability were confirmed. Then eight capable students were chosen a... | PMC10276363 | |
Results | DISEASE | The result showed that the mean and standard deviation of general knowledge, disease symptoms, behavioral risk factors, mid-term outcomes and long-term outcomes, perceived self-efficacy, behavioral beliefs, perceived susceptibility, perceived severity, prevention of stress, healthy food/healthy diet, unhealthy food/unh... | PMC10276363 | |
Conclusions | diabetes | DIABETES | Peer education increased knowledge and improved adolescents' health beliefs and behaviors. Therefore, training in adolescence in order to prevention of diabetes can be considered as an effective step, and the use of peer-led education in this field is recommended. | PMC10276363 |
Trial registration | Trial registration number IRCT20200811048361N1 from School of Public Health & Neuroscience Research Center—Shahid Beheshti University of Medical Sciences. Date applied: 30/12/2020. Date assigned: 01/12/2020. | PMC10276363 | ||
Keywords | PMC10276363 | |||
Background | death, type-2 diabetes, Type-2 diabetes, Diabetes, chronic and metabolic disease | DISEASE, COMPLICATIONS, DIABETES | Diabetes is a chronic and metabolic disease with high levels of blood sugar that leads to several complications [In addition, this serious disease is witnessed as a new clinical condition among children. There has been a surge in the number of type-2 diabetics among children and adolescents across all ethnic groups [In... | PMC10276363 |
Materials & methods | PMC10276363 | |||
Dates periods of recruitment | Participants were enrolled from July 2021 to October 2021 and participated in the intervention from November 2021 to April 2022. | PMC10276363 | ||
Study design and sampling | In this cluster randomized trial study, was performed in Tehran. 168 eighth grade female students (84 students in the intervention group and 84 in the control group) based on their interest and informed consent and their Parents written informed consent participated in the study in 2021.Initially, 14 district (a downto... | PMC10276363 | ||
Sample size | Since, the standard deviation of the study variables was not known to the researcher, therefore based on the following formula, [ | PMC10276363 | ||
Eligible criteria | PMC10276363 | |||
Inclusion criteria | type-1 or type-2 diabetes |
• Students’ willingness for participation• Not suffering from type-1 or type-2 diabetes | PMC10276363 | |
Exclusion criteria | Reluctance to participate in the study at any stage. | PMC10276363 | ||
Data collection tools | Researcher-made questionnaire was used as data collection tool: | PMC10276363 | ||
Designing the instrument: |
1. Systematic review of literature and the relevant instruments: 38 questionnaires, 42 research papers, and 10 theses were consulted to design the questionnaire.2. Determining and designing the items of the instrument through the existing documents, papers, and questionnaires in Iran and other countries: Relevant ques... | PMC10276363 | ||
Reliability and validity | DISEASE | The tool’s validity was checked by face, content and construct validity. To determine face validity, the questionnaire was completed by 20 students. Content validity of the questionnaire was confirmed by qualitative and quantitative methods. In quantitative content analysis, Content Validity Ratio (CVR) and Content Val... | PMC10276363 | |
Intervention | type-2 diabetes, diabetes | DISEASE, TYPE 2 DIABETES, DISEASES, COMPLICATIONS, DIABETES | The educational intervention was through peer education. Peer education has been employed as an effective strategy to combat diseases around the globe. Accordingly, people with shared characteristics such as age, gender, culture, education, and place of residence are assigned the task of imparting information with the ... | PMC10276363 |
Data analysis | In this study Chi-square was used to check the homogeneity of samples as well as the consistency of contributing demographic factors in the research.To check the normality of the data, Skewness and Kurtosis (In interval 2, -2) were calculated. Also, the ANCOVA was performed considering some of assumption, for example: ... | PMC10276363 | ||
Results | This study was conducted on 168 female students in the 14-year-olds age group. See the study steps in the CONSORT diagram (Fig. The participants' descriptive characteristics are listed in Table Demographic variables in intervention and control groups before the interventionIn the intervention group, almost three quarte... | PMC10276363 | ||
Discussion | type-2 diabetes, ’ behavior, diabetes | COMPLICATIONS, DIABETES | The main purpose of this research study was to determine the effect of peer education on knowledge, attitude, and preventive measures against type-2 diabetes among female adolescents. The results show that the peer educational intervention had positive effects on adolescents’ knowledge. Banerjeea et al. also witnessed ... | PMC10276363 |
Implications | type-2 diabetes | TYPE 2 DIABETES | A firm action to take in the prevention of type-2 diabetes is keeping adolescents under control in every place where they spend their time. School setting is considered crucial in promoting and implementing positive changes to adolescents’ habits School health strategies are a critical component of multidisciplinary an... | PMC10276363 |
Limitations and strengths | The limitations of the study include impossibility of assessing the long-term effect of the intervention, individual’s responses to the questions. Another limitation of the study was self-report in response to behavioral questions (instead of objective observation), also since the questionnaire has been validated inter... | PMC10276363 | ||
Conclusion | Type 2 diabetes, diabetes | TYPE 2 DIABETES, TYPE 2 DIABETES, DIABETES | The results of the study show that educational intervention of School-based within peer education framework can contribute to enhanced knowledge and Improve health beliefs and behaviors among female students. Applying this study to a similar population may reduce the risk of Type 2 diabetes in them.Therefore, implement... | PMC10276363 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.